Dipartimento di Scienze Farmaceutiche, Università di Pisa, 56126, Pisa, Italy.
Curr Top Med Chem. 2010;10(10):976-92. doi: 10.2174/156802610791293136.
Adenosine is a ubiquitous homeostatic substance which exerts its action by triggering four different cell membrane G protein-coupled receptors, classified as A(1), A(2A), A(2B), and A(3). Being widely distributed and deeply involved in several physiological functions, as well as pathological disorders, these receptors represent an excellent drug target and the development of specific ligands has been tested as a promising therapeutic concept. Among the obtainable ligands, allosteric modulators offer higher advantages with respect to classical orthosteric compounds, as they possible to achieve greater selectivity and better modulatory control at disease mediating receptors. Actually, synergizing with adenosine bound to the primary binding site, these compounds may modify receptor functions through interaction with an additional binding site. As a consequence, their actions depend directly on the release of the endogenous agonist. A number of compound have been developed as effective allosteric modulators. Most of them target adenosine A(1) and A(3) receptor subtypes as, to date, little or no research attempt have been made to improve the field of A(2A) and A(2B) ligands. This review updates literature on the allosteric modulators that has appeared in the last few years, focusing its attention on medicinal chemistry, in terms of chemical structure and structure-activity relationships. This will provide new perspectives on existing data and an exciting starting point for the development of novel and more effective modulators.
腺苷是一种普遍存在的内稳态物质,通过触发四种不同的细胞膜 G 蛋白偶联受体发挥作用,这些受体被分类为 A(1)、A(2A)、A(2B)和 A(3)。由于广泛分布并深入参与多种生理功能和病理紊乱,这些受体是一个极好的药物靶点,开发特定的配体已被测试为一种有前途的治疗概念。在可获得的配体中,变构调节剂相对于经典的正构化合物具有更高的优势,因为它们可能实现更大的选择性和更好的调节控制在疾病介导的受体。实际上,与结合在主要结合位点的腺苷协同作用,这些化合物可以通过与附加结合位点的相互作用来改变受体功能。因此,它们的作用直接取决于内源性激动剂的释放。已经开发了许多作为有效变构调节剂的化合物。它们中的大多数针对腺苷 A(1)和 A(3)受体亚型,因为迄今为止,几乎没有或没有尝试改善 A(2A)和 A(2B)配体的领域。这篇综述更新了近年来出现的变构调节剂的文献,重点关注药物化学,从化学结构和结构-活性关系的角度。这将为现有数据提供新的视角,并为开发新型、更有效的调节剂提供一个令人兴奋的起点。